Skip to main content
. Author manuscript; available in PMC: 2022 May 1.
Published in final edited form as: Nat Biomed Eng. 2021 Nov 1;5(11):1320–1335. doi: 10.1038/s41551-021-00805-x

ED Fig. 7. BML-210 promotes the expression of genes in the antigen presentation of breast tumour cells.

ED Fig. 7

a,b, Confocal images showing H-2Kb and HLA-A2 on OVA+ EO771 cells (a) and NY-ESO-1+ MDA-MB-468 cells (b), respectively. The immunofluorescence images were analyzed by ImageJ. c, Quantitative analysis of confocal images in (a) for assessing H-2Kb antigen presentation. d, Quantitative analysis of confocal images in (b) for assessing HLA-A2 antigen presentation. e, Western blot showing B2M protein expression levels in OVA+ EO771 cells treated with BML-210 drug with 0, 0.1, 1 μM for 48h. f, Western blot showing B2M knockdown in OVA+ EO771 cells. One-way ANOVA test was conducted for statistical analysis in (c,d). Data are presented as mean ± SD. ****, p < 0.0001.